ETS-targeted therapy: can it substitute for MEK inhibitors?

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The RAS/MAPK pathway is frequently activated in various cancers, with ERK1 and ERK2 being key components.
• While MEK inhibitors show promise pre-clinically, their clinical efficacy is limited in most tumors due to feedback loop disruptions.
• ETS1 and ETS2 transcription factors are major downstream effectors of the MAPK pathway and represent potential therapeutic targets.

Purpose of the Study:

• To explore ETS1 and ETS2 as alternative therapeutic targets in cancer, addressing the limitations of current MEK inhibitors.
• To investigate strategies for modulating ETS transcription factors, including proteolysis and interface targeting.

Main Methods:

• Analysis of the RAS/MAPK pathway and the role of ERK1/ERK2 activation in cancer.
• Review of existing MEK inhibitor limitations and the development of second-generation inhibitors.
• Exploration of therapeutic strategies targeting ETS1 and ETS2, such as promoting proteolysis and inhibiting protein interactions.

Main Results:

• Limited clinical success of MEK inhibitors is often due to loss of negative feedback regulation in the MAPK pathway.
• Targeting ETS1 for proteolysis via Src or USP9X inhibitors is a potential strategy to accelerate protein turnover.
• Modulating ETS1/ETS2 interactions with cofactors like CBP/p300 and BRD4 presents novel therapeutic avenues.

Conclusions:

• ETS-targeted therapy shows promise as an alternative to MEK inhibitors for cancer treatment.
• A potential challenge is the inhibition of negative feedback loops, potentially leading to resistance via ERK activation.
• Further investigation is required to develop clinically viable strategies for inhibiting ETS1 and ETS2.